Treakisym bendamustine: Phase II discontinued

SymBio discontinued an open-label, Japanese Phase II trial after 90 mg/m 2 bendamustine failed to achieve "the expected level of efficacy as a single agent" in 17 evaluable patients with refractory or relapsed MM. SymBio and partner Eisai said they will re-examine the development strategy for relapsed and refractory MM in Japan and consider the development strategy of the drug being used in the U.S. and EU, where it being evaluated as a combination therapy. Bendamustine is also in Phase II testing in Japan for front-line low-grade non-Hodgkin's lymphoma (NHL), refractory and relapsed diffuse large B cell lymphoma (DLBCL) and front-line chronic lymphocytic leukemia (CLL). ...